NEC Settlement Amounts 2026: Abbott $670M Settlement Explained

NEC settlement amounts entered public view in 2026 through one of the year’s largest resolutions — and one of the most misread. This guide sets out what Abbott actually disclosed, why the widely quoted per-infant arithmetic does not work, and why the federal and state records point in opposite directions.

Where the Litigation Stands

These claims allege that cow’s-milk-based preterm infant formulas — principally Abbott’s Similac and Mead Johnson’s Enfamil specialty products — increased the risk of necrotising enterocolitis, a severe intestinal condition affecting premature infants, and that the manufacturers failed to warn.

The litigation is unusual in its shape. The federal MDL is comparatively small at 825 pending actions, while the substantial majority of claims are in state courts — particularly Missouri and Illinois. That matters because the two forums have produced almost opposite outcomes.

The $670 Million Abbott Settlement

On 20 August 2026 Abbott disclosed a settlement of approximately $670 million. The details come from Abbott’s own filing rather than a press report, which makes them unusually reliable:

• It resolves the Missouri Gill case — the $495 million jury verdict returned in July 2024 and affirmed on appeal in May 2026.
• It also resolves NEC claims involving approximately 2,000 additional infants.
• Abbott characterises it as a compromise of disputed claims, expressly not an admission of liability.

Abbott also disclosed what remains: roughly 1,700 lawsuits covering claims on behalf of approximately 12,700 infants. The company noted that this population includes overlapping claims, infants diagnosed with NEC before receiving any formula, and cases naming several manufacturers without identifying whose product was actually used — all of which it will contest.

NEC Settlement Amounts: Why There Is No Reliable Per-Infant Average

The obvious calculation — $670 million divided by 2,000 infants, giving roughly $335,000 each — is being repeated widely and is not sound.

The reason is in Abbott’s own description. The $670 million resolves the Gill case and the claims of approximately 2,000 other infants. Gill was a $495 million verdict that had already been affirmed on appeal, meaning it carried real, quantified exposure at the point of settlement. If a substantial share of the $670 million is attributable to resolving Gill, the amount remaining for the other 2,000 infants is far smaller than a straight division implies.

Abbott has not disclosed the allocation. Without it, no per-infant figure can be derived from public information, and any source presenting one is guessing. What can be said is that individual amounts will be tiered by severity, and that fees, costs and liens are deducted before a family receives anything.

The Split Record: State Wins, Federal Losses

NEC claims have produced very large state-court verdicts and, so far, no federal trial wins at all. Both halves matter.

Date	Defendant	Forum	Outcome
March 2024	Mead Johnson (Enfamil)	State court	$60 million for the plaintiff
July 2024	Abbott (Similac)	Missouri state court	$495 million — affirmed on appeal May 2026
October 2024	Mead Johnson	Missouri state court	Defence verdict
April 2026	Abbott (Similac)	State court	$70 million, involving four families
July 2026	Mead Johnson	State court	Defence verdict

In the federal MDL the picture is different: Abbott has won the first three bellwethers on summary judgment, meaning those cases were dismissed before reaching a jury. That is a significant defence result, because summary judgment turns on whether the plaintiff’s evidence is legally sufficient rather than on how a jury weighs it.

The practical reading is that forum and evidence quality matter enormously in this litigation. A claim with strong product identification and clear medical causation in a favourable state venue is in a very different position from one in the federal MDL facing the same summary-judgment arguments that defeated the first three bellwethers.

Factors That Affect Claim Value

• Product identification — hospital records showing which manufacturer’s formula was administered. Abbott has explicitly flagged claims that fail to identify a product, and this is the single most common weakness.
• Timing of diagnosis — NEC diagnosed before formula was given undercuts causation, and Abbott has said the remaining claim population includes such cases.
• Gestational age and birth weight — central to both risk and causation arguments.
• Severity and outcome — surgical intervention, bowel resection, long-term complications, or infant death.
• Medical documentation — NICU records, feeding logs, pathology and imaging.
• Forum — state court and federal MDL claims have followed markedly different trajectories.

Who Qualifies

Claims typically involve a premature infant who received cow’s-milk-based preterm formula in a hospital setting and was subsequently diagnosed with necrotising enterocolitis, with records establishing which product was used and when.

Because Abbott’s settlement covers a defined group, whether a particular claim is inside or outside it is a specific question. Claims against Mead Johnson are entirely separate — Reckitt has not settled and has won two trials.

What Happens Next

Abbott’s settlement moves roughly 2,000 infant claims into administration, but leaves around 12,700 infants’ claims outstanding across approximately 1,700 lawsuits. Whether Abbott extends the settlement structure to that larger group, and on what terms, is the central open question.

Until that question is answered, NEC settlement amounts for the remaining claims cannot be estimated from Abbott’s figure. Mead Johnson’s position is different again: having won trials in October 2024 and July 2026, it has less pressure to settle, and claims against it are likely to be litigated further.

Use the NEC Settlement Calculator

Our free NEC Settlement Calculator helps organise the birth history, product identification and medical documentation that determine whether a claim is viable and how it is likely to be valued. It produces an educational estimate, not an offer.

How an NEC Settlement Is Actually Paid

Abbott announced a total. It did not announce an allocation, and the distance between those two things is where most misreporting of NEC settlement amounts happens. Even once an individual figure is agreed, several deductions sit between it and the family.

The first is the contingency fee and case expenses set out in the retainer agreement. The second is lien repayment. NEC cases involve extended neonatal intensive care, surgery and in many cases years of follow-up, and that care was almost always paid for by someone — a private insurer, Medicaid or CHIP. Those payers have a right to be reimbursed out of the settlement, and in this litigation the sums involved are frequently substantial.

There is a third step that most mass torts do not have. Where the claimant is a surviving child, a settlement generally requires court approval, and courts commonly direct that some or all of the net proceeds be placed in a structured settlement, an annuity or a restricted account until the child reaches majority. That protects the child, and it means the money may not be immediately available even after everything is agreed.

The practical consequence is that no honest source can tell a family what they will receive from Abbott’s settlement. The total is public. The allocation, the fee, the liens and the structure are not.

What to Gather Before Speaking to a Lawyer

NEC claims are proved or lost on the NICU feeding record. It is the document that shows which formula or human-milk fortifier an infant received, on which days, and in what volume — and without it, product identification is guesswork. It is also the document families are least likely to already hold, because it usually does not appear in a discharge summary.

Hospitals in the United States are obliged to provide complete medical records on request, and parents can make that request directly. It is worth asking specifically for the NICU nursing and feeding flowsheets rather than a general records request, because a summary will not contain the detail a claim needs.

Alongside feeding records, the essential documents are the radiology and clinical notes confirming necrotising enterocolitis and its stage, operative reports for any bowel resection or ostomy, records of short bowel syndrome or feeding intolerance that followed, and the birth record establishing gestational age and birth weight. Prematurity is central to both eligibility and causation, so those two numbers matter more here than in almost any other mass tort.

Limitation periods differ for claims brought on behalf of a minor child, and in many states they are extended — sometimes considerably. That is not a reason to delay, but it does mean a family who assumed it was too late should have the question answered properly rather than assumed.

Common Misconceptions About NEC Settlement Amounts

“$670 million divided by 2,000 infants is about $335,000 each.”

This is the single most repeated error in current NEC coverage, and it does not work. Abbott’s own disclosure describes the settlement as resolving the Gill case and the claims of approximately 2,000 additional infants. Gill was a $495 million verdict that had already been affirmed on appeal, so it carried real, quantified exposure. If a substantial share of the $670 million is attributable to resolving that single case, what remains for the other 2,000 infants is far smaller than a straight division implies. The allocation has not been disclosed, so the honest answer is that no per-infant figure exists.

“Abbott settled, so the NEC litigation is over.”

It is not close to over. Approximately 1,700 lawsuits covering claims for around 12,700 infants remain pending across federal and state courts. Abbott’s settlement covers a defined group; whether it will be extended to the larger population, and on what terms, is the central open question in this litigation.

“Mead Johnson will have to settle too.”

Mead Johnson has not settled and is in a materially stronger position than Abbott was. It won defence verdicts in October 2024 and again in July 2026. A defendant with recent trial wins has less pressure to resolve, and claims against Enfamil products are likely to be litigated considerably further than claims against Similac.

“A settlement means Abbott admitted the formula caused NEC.”

Abbott expressly describes the settlement as “a compromise of disputed claims and not in any way an admission of liability.” That language is standard, and it is not merely cosmetic here: Abbott has won the first three federal bellwethers on summary judgment, meaning those cases were dismissed before reaching a jury. Causation in NEC cases remains genuinely contested.

“The $495 million and $70 million verdicts show what NEC claims are worth.”

They show what two juries awarded in two specific cases in favourable state venues, on facts that included clear product identification and severe outcomes. The $70 million verdict in April 2026 involved four families, so it is not a single-claimant figure at all. Meanwhile Abbott has won the first three federal bellwethers on summary judgment, and Mead Johnson has won two defence verdicts. A verdict record that runs from nine figures to nothing is not a guide to individual value; it is evidence that outcome depends heavily on forum and on the strength of the records behind the claim.

“Any premature baby who developed NEC has a claim.”

Necrotising enterocolitis occurs in premature infants who were never given cow’s-milk-based formula, and prematurity itself is the dominant risk factor. A viable claim needs documented administration of a specific product, a confirmed NEC diagnosis, and a treating record that supports causation. Where the NICU feeding log shows exclusive human milk, or where the product cannot be identified at all, the claim faces the same summary-judgment arguments that ended the first three federal bellwethers.

“Hospital-supplied fortifiers are not part of this.”

Human-milk fortifiers and preterm formulas supplied directly by a hospital are within the scope of this litigation where they are cow’s-milk-based products made by the defendant manufacturers. Families frequently assume that because they never bought a tin, no product claim exists. What matters is what was administered in the NICU, not who paid for it — which is another reason the feeding record is the document that decides these cases.

Frequently Asked Questions

How much is the NEC baby formula settlement per infant?

No per-infant figure has been disclosed, so published NEC settlement amounts describe the total, not what any one family receives. Abbott’s approximately $670 million settlement covers both the Missouri Gill case and the claims of roughly 2,000 additional infants, and the allocation between them is not public. Dividing $670 million by 2,000 produces a misleading number, because Gill was a $495 million verdict already affirmed on appeal.

Has Abbott settled all NEC claims?

No. Abbott disclosed that approximately 1,700 lawsuits covering around 12,700 infants remain pending after the August 2026 settlement.

Has Mead Johnson settled?

No. Reckitt’s Mead Johnson unit has not announced a settlement and has won defence verdicts in October 2024 and July 2026.

What happened in the federal MDL bellwethers?

Abbott won the first three on summary judgment, meaning the cases were dismissed before trial. The large plaintiff verdicts in this litigation have come from state courts, not the federal MDL.

Can I still file an NEC claim?

Claims are still being filed. Product identification is critical — hospital records showing which formula was administered — and limitation periods vary by state, generally running from diagnosis or from discovery of the connection.

Sources

The settlement terms on this page come from Abbott’s own securities disclosure. No per-claimant figure is stated because none has been published.

• Abbott Laboratories — Form 8-K disclosing the NEC settlement — source for the $670 million figure, the scope covering Gill plus approximately 2,000 infants, and the outstanding claim population.
• Judicial Panel on Multidistrict Litigation — Pending MDL Dockets — source for MDL 3026 pending action counts.
• U.S. District Court, Northern District of Illinois — the court administering MDL 3026 before Judge Rebecca Pallmeyer.
• NIH NICHD — Necrotizing Enterocolitis — medical background on NEC in preterm infants.
• U.S. Food and Drug Administration — Infant Formula — federal regulatory background.

Related NEC Resources

• NEC Baby Formula Lawsuit — eligibility, injuries and how claims are filed.
• NEC Settlement Calculator — organise birth history and product records.
• Dangerous Drug & Product Liability Lawsuits — other active product claims.
• Settlement Amounts — payout guides across all case types.

About the Author

Mason Arnao is a legal content strategist and mass tort researcher at TortAdvisor.com. He covers emerging litigation, settlement trends, and consumer legal rights across pharmaceutical, product liability, and personal injury law.